SCHEMBL467281

SCHEMBL467281

CC(C)(C)OC(=O)Nc1ccc(Br)cc1

nearest known ligand 0.59

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 4/20 0.56
MEN1 O00255 3/20 0.56
NPC1 O15118 2/20 0.56
RAB9A P51151 2/20 0.56
SMN1; SMN2 Q16637 3/20 0.54
RECQL P46063 1/20 0.54
CYP17A1 P05093 2/20 0.52
BCL2 P10415 5/20 0.52
BECN1 Q14457 3/20 0.52
LMNA P02545 2/20 0.50
PSMB8 P28062 1/20 0.50
POLB P06746 1/20 0.50
GAA P10253 1/20 0.50
PKM P14618 1/20 0.50
NAMPT P43490 1/20 0.50
HPGD P15428 1/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL206442 0.95 CYP17A1 (0.59) KMT2AMEN1NPC1RAB9ASMN1; SMN2
SCHEMBL31483499 0.92 ALDH1A1 (0.52) KMT2AMEN1NPC1RAB9ASMN1; SMN2
SCHEMBL13055402 0.90 CYP17A1 (0.59) SMN1; SMN2CYP17A1PSMB8GAANAMPT
SCHEMBL24891748 0.87 FPR3 (0.49) KMT2AMEN1NPC1RAB9ASMN1; SMN2
SCHEMBL23619661 0.85 SMN1; SMN2 (0.62) NPC1RAB9ASMN1; SMN2CYP17A1LMNA
SCHEMBL20865536 0.85 CYP17A1 (0.68) SMN1; SMN2CYP17A1PSMB8NAMPT
SCHEMBL23011482 0.84 CYP17A1 (0.56) CYP17A1BCL2BECN1PSMB8NAMPT
SCHEMBL30452006 0.84 CA12 (0.47) KMT2AMEN1NPC1RAB9ASMN1; SMN2
SCHEMBL10200217 0.84 CA12 (0.47) KMT2AMEN1NPC1RAB9ASMN1; SMN2
SCHEMBL8196446 0.84 CYP17A1 (0.51) KMT2AMEN1NPC1RAB9ASMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 313 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-117800875-B Preparation method of trans- (N-Boc-4-aminocyclohexyl) acetic acid 泰州精英化成医药科技有限公司 2024-10-22 CN claimed
CN-117800875-A Preparation method of trans- (N-Boc-4-aminocyclohexyl) acetic acid 泰州精英化成医药科技有限公司 2024-04-02 CN claimed
CN-114591252-A Triazole feed additive and preparation method and application thereof 河南湾流生物科技有限公司 2022-06-07 CN claimed
WO-2026098560-A2 BENZENE-CONTAINING POLYCYCLIC DERIVATIVE MODULATOR, PREPARATION METHOD THEREFOR AND USE THEREOF 上海翰森生物医药科技有限公司 2026-05-15 WO disclosed
US-12612408-B2 Pyrazolone-fused pyrimidine compound, preparation method for same and applications thereof SHANGHAI PHARMACEUTICALS HOLDING CO., LTD. (CN) 2026-04-28 US disclosed
EP-4355741-B1 SOS1 PROTEIN DEGRADERS, PHARMACEUTICAL COMPOSITIONS THEREOF, AND THEIR THERAPEUTIC APPLICATIONS BIOTHERYX INC (US) 2025-12-10 EP disclosed
EP-4631952-A1 GLUCOCORTICOID RECEPTOR AGONIST AND CONJUGATE THEREOF Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. (CN) 2025-10-15 EP disclosed
US-20250281433-A1 NOVEL DERIVATIVE COMPOUND HAVING BIPHENYL GROUP INTRODUCED INTO AMINO-ALKANOIC ACID AND ANTI-INFLAMMATORY COMPOSITION COMPRISING SAME AMTIXBIO CO., LTD. (KR) 2025-09-11 US disclosed
CN-120051471-A Novel heterocyclic compound 首药控股(北京)股份有限公司 2025-05-27 CN disclosed
WO-2025099451-A1 NEW COMPOUNDS AND METHODS Transition Bio Limited (GB) 2025-05-15 WO disclosed
EP-4551570-A1 NOVEL COMPOUNDS AS GCN2 INHIBITORS, PHARMACEUTICAL COMPOSITIONS AND USES THEREOF Dong-A ST Co., Ltd. (KR) 2025-05-14 EP disclosed
EP-0860428-A2 Sulphonamide derivatives ELI LILLY AND COMPANY (US) 1998-08-26 EP disclosed
WO-1998033496-A1 SULPHONAMIDE DERIVATIVES ELI LILLY AND COMPANY (US) 1998-08-06 WO disclosed
US-5789434-A ACID, ESTER OR AMIDE DERIVATIVES AS ANTIINFLAMMATORY AGENTS, ANTIARTHRITIC AGENTS AND REDUCTION OF CARTILAGE DETERIORATION BAYER CORPORATION (US) 1998-08-04 US disclosed
CN-1163604-A Substituted 4-diarylbutanoic or 5-diarylpentanoic acids and derivatives thereof as matrix metalloproteinase inhibitors BAYER AG (US) 1997-10-29 CN disclosed
EP-0790974-A1 SUBSTITUTED 4-BIARYLBUTYRIC OR 5-BIARYLPENTANOIC ACIDS AND DERIVATIVES AS MATRIX METALLOPROTEASE INHIBITIORS Bayer Corporation (US) 1997-08-27 EP disclosed
WO-1996015096-A1 SUBSTITUTED 4-BIARYLBUTYRIC OR 5-BIARYLPENTANOIC ACIDS AND DERIVATIVES AS MATRIX METALLOPROTEASE INHIBITIORS BAYER CORPORATION (US) 1996-05-23 WO disclosed
US-5484786-A ANTIALLERGENS, ANTIINFLAMMATORY AGENTS ABBOTT LABORATORIES (US) 1996-01-16 US disclosed
US-5096919-A Pyrrolylphenyl-substituted hydroxamic acid derivatives CIBA-GEIGY CORPORATION (US) 1992-03-17 US disclosed
EP-0378991-A1 Certain pyrrolylphenyl-substituted hydroxamic acid derivatives CIBA-GEIGY AG (CH) 1990-07-25 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250281433-A1 NOVEL DERIVATIVE COMPOUND HAVING BIPHENYL GROUP INTRODUCED INTO AMINO-ALKANOIC ACID AND ANTI-INFLAMMATORY COMPOSITION COMPRISING SAME AADAT, AADAC, AHR KMT2A 635/4885MEN1 4383/4885NPC1 3526/4885
US-12612408-B2 Pyrazolone-fused pyrimidine compound, preparation method for same and applications thereof WEE1, WEE2, TK1 KMT2A 3554/4885MEN1 3056/4885NPC1 842/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.